The UK and US have forged a important bilateral deal that will guarantee zero tariffs on UK pharmaceutical exports going into the US market.
Key Provisions of the Deal
Under the terms of the agreement, the UK has committed to increase funding on pharmaceuticals through the public health system. This move secures that duties on these key products will be held at zero for a period of 36 months.
This development comes after recent threats to hike duties on patented drug imports, with potential rates mentioned as high as 100%.
"This agreement between the UK bolsters the worldwide climate for cutting-edge drugs and brings long-overdue balance to American-British pharmaceutical trade," an announcement declared.
Commercial Impact
Pharmaceuticals constitute one of the the United Kingdom's largest exports to the America, which is clearly the biggest market for major companies like GSK and AstraZeneca.
Export figures indicate that in the one-year period to the end of the third quarter, the UK shipped pharmaceutical products valued at billions to the US. This value made up a significant portion of British export trade in that timeframe.
"This guarantee secures work, stimulates funding and facilitates the UK to become a global hub for medical research," the Business and Trade Secretary stated.
Specific UK Commitments
The pact includes several specific commitments from the UK:
- Revised Affordability Limit: The UK will lift the price threshold at which it deems new treatments to be prohibitively costly by twenty-five percent.
- Increased NHS Spending: There is a target to increase overall public funding on treatments from 0.3 percent of GDP to 0.6% over the next decade.
- Payback Limit: The sum pharmaceutical firms must pay back to the NHS to control costs will be restricted at fifteen percent. Last year, repayments topped twenty percent.
Broader Context
This agreement takes place against a long-running tension between the drug companies and the UK government over medicine costs and regulatory access.
This friction were heightened by assertions that US patients were charged significantly more for the same drugs than people in the UK and Europe.
Recently, several major drug company projects in the UK have been halted or scrapped, while multi-billion-dollar investments have been directed toward American operations.
A senior figure acknowledged that the NHS had to increase expenditure on treatments, noting that its expenditure on drugs had decreased as a proportion of its overall budget over the last ten years.
